Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SI | P14410 | 2/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128153 | 0.77 | CYP4F2 (0.44) | ALDH1A1TSHRMGAMGAASI | |
| SCHEMBL1902123 | 0.76 | — | — | |
| SCHEMBL809243 | 0.75 | DGAT1 (0.40) | DGAT1ALDH1A1POLBTSHRKCNN4 | |
| SCHEMBL131854 | 0.73 | HCAR2 (0.38) | ALDH1A1TSHR | |
| SCHEMBL127989 | 0.73 | TSHR (0.39) | TSHR | |
| SCHEMBL28476981 | 0.73 | DGAT1 (0.32) | DGAT1ALDH1A1POLB | |
| SCHEMBL2477744 | 0.72 | CYP4F2 (0.39) | DGAT1ALDH1A1POLBTSHRKCNN4 | |
| SCHEMBL2475483 | 0.72 | DGAT1 (0.44) | DGAT1ALDH1A1POLBTSHRKCNN4 | |
| SCHEMBL29674742 | 0.72 | DGAT1 (0.39) | DGAT1ALDH1A1POLBTSHRKCNN4 | |
| SCHEMBL11471022 | 0.71 | DGAT1 (0.42) | DGAT1ALDH1A1TSHRKCNN4MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101835757-B | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE | 2014-03-05 | — | — | CN | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101835757-A | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | DGAT1 2027/4885ALDH1A1 580/4885POLB 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.